EA200400742A1 - Водный инъекционный раствор антагониста lhrh и способ его получения - Google Patents

Водный инъекционный раствор антагониста lhrh и способ его получения

Info

Publication number
EA200400742A1
EA200400742A1 EA200400742A EA200400742A EA200400742A1 EA 200400742 A1 EA200400742 A1 EA 200400742A1 EA 200400742 A EA200400742 A EA 200400742A EA 200400742 A EA200400742 A EA 200400742A EA 200400742 A1 EA200400742 A1 EA 200400742A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lhrh antagonist
mortar
obtaining
water injection
lhrh
Prior art date
Application number
EA200400742A
Other languages
English (en)
Other versions
EA010787B1 (ru
Inventor
Вернер Сарликиотис
Хорст Бауэр
Маттиас Ришер
Юрген Энгель
Франк Гютлейн
Доминико Ди Стефано
Original Assignee
Центарис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Центарис Гмбх filed Critical Центарис Гмбх
Publication of EA200400742A1 publication Critical patent/EA200400742A1/ru
Publication of EA010787B1 publication Critical patent/EA010787B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Представлен водный инъекционный раствор антагониста LHRH содержащий кроме антагониста LHRH такого как цетрореликс, органическую физиологически совместимую кислоту и, необязательно, поверхностно-активное вещество, а также структурирующий компонент. Антагонист LHRH имеет в значительной мере улучшенную растворимость и может быть приготовлен в более высоких концентрациях и с повышенной биодоступностью. Тенденция антагониста LHRH к агрегации значительно снижена.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400742A 2001-11-26 2002-11-15 Водный инъекционный раствор антагониста lhrh и способ его получения EA010787B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10157628A DE10157628A1 (de) 2001-11-26 2001-11-26 Injektionslösung eines LHRH-Antagonisten
PCT/EP2002/012798 WO2003045419A1 (de) 2001-11-26 2002-11-15 Injektionslösung eines lhrh-antagonisten

Publications (2)

Publication Number Publication Date
EA200400742A1 true EA200400742A1 (ru) 2004-12-30
EA010787B1 EA010787B1 (ru) 2008-10-30

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400742A EA010787B1 (ru) 2001-11-26 2002-11-15 Водный инъекционный раствор антагониста lhrh и способ его получения

Country Status (33)

Country Link
EP (1) EP1448221B1 (ru)
JP (1) JP4343693B2 (ru)
KR (1) KR100936636B1 (ru)
CN (1) CN100404068C (ru)
AR (1) AR037424A1 (ru)
AT (1) ATE350050T1 (ru)
AU (1) AU2002365504B2 (ru)
BR (1) BRPI0214412B8 (ru)
CO (1) CO5580793A2 (ru)
CY (1) CY1106401T1 (ru)
DE (2) DE10157628A1 (ru)
DK (1) DK1448221T3 (ru)
EA (1) EA010787B1 (ru)
ES (1) ES2276970T3 (ru)
GE (1) GEP20063861B (ru)
HK (1) HK1073078A1 (ru)
HR (1) HRP20040587B1 (ru)
HU (1) HU230992B1 (ru)
IL (2) IL161894A0 (ru)
IS (1) IS2725B (ru)
ME (1) ME00499B (ru)
MX (1) MXPA04005018A (ru)
NO (1) NO333364B1 (ru)
NZ (1) NZ533712A (ru)
PL (1) PL206199B1 (ru)
PT (1) PT1448221E (ru)
RS (1) RS51408B (ru)
RU (1) RU2322969C2 (ru)
SI (1) SI1448221T1 (ru)
TW (1) TWI312283B (ru)
UA (1) UA81612C2 (ru)
WO (1) WO2003045419A1 (ru)
ZA (1) ZA200404051B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP2526950A1 (en) 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
KR20110007614A (ko) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
CN103690560B (zh) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 一种转化糖电解质注射液药物组合物及其制备方法
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
RU2614234C2 (ru) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция на основе 3-(4-Метилимидазол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства
RU2019127027A (ru) * 2017-01-30 2021-03-01 Энтив Лимитед КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПО МЕНЬШЕЙ МЕРЕ ОДИН АНТАГОНИСТ GnRH
HRP20211890T1 (hr) 2019-10-24 2022-03-04 Sun Pharmaceutical Industries Ltd Stabilan parenteralni dozni oblik cetroreliks acetata

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
UA73956C2 (en) * 1999-09-23 2005-10-17 Zentaris Gmbh Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung

Also Published As

Publication number Publication date
ME00499B (me) 2011-10-10
IL161894A (en) 2014-05-28
IS7251A (is) 2004-05-06
WO2003045419A1 (de) 2003-06-05
UA81612C2 (ru) 2008-01-25
KR100936636B1 (ko) 2010-01-14
ZA200404051B (en) 2005-05-25
IL161894A0 (en) 2005-11-20
JP4343693B2 (ja) 2009-10-14
PL369548A1 (en) 2005-05-02
IS2725B (is) 2011-03-15
NO333364B1 (no) 2013-05-13
HK1073078A1 (en) 2005-09-23
RS51408B (sr) 2011-02-28
TWI312283B (en) 2009-07-21
EP1448221B1 (de) 2007-01-03
AU2002365504A1 (en) 2003-06-10
ATE350050T1 (de) 2007-01-15
ES2276970T3 (es) 2007-07-01
BR0214412A (pt) 2004-09-14
PT1448221E (pt) 2007-03-30
AR037424A1 (es) 2004-11-10
BRPI0214412B1 (pt) 2016-01-05
EA010787B1 (ru) 2008-10-30
DK1448221T3 (da) 2007-03-19
AU2002365504B2 (en) 2007-06-28
HRP20040587B1 (en) 2008-01-31
JP2005510544A (ja) 2005-04-21
HRP20040587A2 (en) 2004-10-31
DE50209193D1 (de) 2007-02-15
DE10157628A1 (de) 2003-06-12
CY1106401T1 (el) 2011-10-12
EP1448221A1 (de) 2004-08-25
SI1448221T1 (sl) 2007-06-30
GEP20063861B (en) 2006-06-26
HUP0401986A3 (en) 2012-09-28
CN100404068C (zh) 2008-07-23
PL206199B1 (pl) 2010-07-30
BRPI0214412B8 (pt) 2021-05-25
CO5580793A2 (es) 2005-11-30
KR20040058312A (ko) 2004-07-03
NO20042449L (no) 2004-06-11
MXPA04005018A (es) 2004-08-11
RS44904A (en) 2006-10-27
NZ533712A (en) 2006-01-27
HUP0401986A2 (hu) 2005-01-28
HU230992B1 (hu) 2019-08-28
CN1592630A (zh) 2005-03-09
RU2004119821A (ru) 2005-04-20
RU2322969C2 (ru) 2008-04-27
TW200300352A (en) 2003-06-01

Similar Documents

Publication Publication Date Title
EA200400742A1 (ru) Водный инъекционный раствор антагониста lhrh и способ его получения
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
AR100291A2 (es) Composición catártica
EA200501285A1 (ru) Способ получения липосомальных препаратов
ATE294828T1 (de) Neue polythiophen-dispersionen
EA200500181A1 (ru) Композиции и способы обработки подземных пород
DK0996429T3 (da) Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
NZ593214A (en) Compounds and Processes for preparing serine protease inhibitors
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
RU2010122376A (ru) Способ обработки призабойной зоны скважины
CA2412759A1 (en) Injectable solution of an lhrh antagonist
TW200519080A (en) Agent containinf (2R)-2-propyloctanic acid as effective component
ITMI20032463A1 (it) Soluzione acquosa concentrata a base di ambroxolo
RU2007138689A (ru) Способ обработки призабойной зоны пласта
ATE526988T1 (de) Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
EA200201232A1 (ru) Производные сульфонамида
DE50307211D1 (de) Formkörper mit nachträglicher Tensiddosierung
RU2003125470A (ru) Способ подращивания личинок осетровых рыб
RU2000123568A (ru) Способ изоляции обводнившихся участков пласта
EA200000772A1 (ru) Фармацевтические композиции и способы их приготовления
ES2050978T3 (es) Procedimiento de recuperacion de galio a partir de soluciones basicas que lo contienen.
EA200300249A1 (ru) Промежуточные соединения для использования при получении витамина e
RU2003118270A (ru) Способ стабилизации и активации гидролитических ферментов
RU96112729A (ru) Способ разработки нефтяной залежи

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ KZ KG MD TJ TM